Gliknik Inc

BiotechnologyBiotechnologyImmunologyBiologics

📍 Baltimore, MD, United States• Founded 2007

StreetZero Signal 79

Be the first to signal interest

About Gliknik Inc

Gliknik Inc. is a Baltimore-based immunology company focused on discovering and developing innovative biologics for cancer and autoimmune disorders. It leverages its Stradobody platform to create first-in-class drug candidates. The company has advanced multiple compounds into clinical trials and maintains a pipeline targeting immune modulation. Its headquarters is at 801 West Baltimore Street, Baltimore, MD.

LATEST FUNDINGPrivate Placement

$15.0M

Announced 2026-09-17

TOTAL RAISED$125M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Gliknik Inc.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2007

HQBaltimore, MD, United States

Industry

Biotechnology

Tags

BiotechnologyImmunologyBiologicsClinical Trials

Investors

First In Ventures SAISO Partners RDA Ventures Garden Street Holdings Baxter Ventures

Key highlights

Raised $11.5M Series C in 2021 to advance three drug candidates.
Total funding reached $125M per PitchBook data.
Licensed GL-2045 to Pfizer with $25M upfront payment.
Received SBIR Phase II funding and MIPS support for Stradobody platform.
HQ located at 801 W Baltimore St, Baltimore, MD.

Ask StreetZero about Gliknik Inc

Put our AI to work on this deal.

What is Gliknik Inc's value proposition?Who are Gliknik Inc's competitors?Why does this raise matter?Summarize Gliknik Inc for an investor.

Similar companies

Other Biotechnology deals, ranked by Signal.

Moonwalk Biosciences, Inc.

Iambic Therapeutics, Inc.

Airway Therapeutics, Inc.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account